Syndecan-1 is overexpressed during atherogenesis

Vo, Sophie; Charnaux, Nathalie; Richard, Benjamin

doi:10.1016/j.atherosclerosis.2015.04.266

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The protective role associated with a normal HDL is mainly attributed to its pleiotropic effects [35], such as antioxidative, antiapoptotic, anti-inflammatory, antithrombotic or antiproteolytic activity on endothelial cells, thus preventing glycocalyx injury and the subsequent syndecan-1 release. Supplementary, syndecan-1 is overexpressed in atheromatous lesions of the aorta, such as fatty streaks and fibrolipid lesions, but also in intimal smooth muscle cells, thus further stimulating the formation of foam cells and making the atheroma plaque even more vulnerable [8,36]. The expression of syndecan-1 even in early lesions may render reasonable its inclusion in some currently available risk scores or even as a marker of subclinical atherosclerosis [37].…”

Section: Discussionmentioning

confidence: 99%

Syndecan-1: From a Promising Novel Cardiac Biomarker to a Surrogate Early Predictor of Kidney and Liver Injury in Patients with Acute Heart Failure

Miftode

Costache

Constantinescu

et al. 2023

Life

View full text Add to dashboard Cite

(1) Background: Acute heart failure (HF) represents a complex clinical syndrome burdened by increased mortality and a high rate of systemic complications. Although natriuretic peptides (e.g., NT-proBNP) currently represent the diagnostic and prognostic gold standard in acute HF, those molecules do not accurately reflect all the pathophysiological mechanisms involved in the progression of this pathology when determined independently. Therefore, the current paradigm tends to focus on a multi-marker approach for the risk stratification of patients with acute HF. Syndecan-1 is a less studied biomarker in cardiovascular diseases; its assessment in patients with acute HF being potentially able to reflect the myocardial pathological changes, such as fibrosis, inflammation, endothelial dysfunction or global wall stress. (2) Methods: We conducted a single center prospective study that enrolled 173 patients (120 patients admitted for acute HF, compared to 53 controls with stable chronic HF). A complete standardized clinical, echocardiography and laboratory evaluation was performed at admission, including serum samples for the determination of syndecan-1 by the enzyme-linked immunosorbent assay (ELISA) method. (3) Results: The serum concentration of syndecan-1 was significantly higher in patients with acute HF, compared to controls [121.4 (69.3–257.9) vs. 72.1 (41.4–135.8) ng/mL, p = 0.015]. Syndecan-1 was a significant predictor for the diagnosis of acute HF, expressed by an area under the curve (AUC) of 0.898, similar to NT-proBNP (AUC: 0.976) or cardiac troponin (AUC: 0.839). Moreover, syndecan-1 was independently associated with impaired kidney and liver function at admission, being also a predictor for early, subclinical organ dysfunction in patients with normal biological parameters at admission. When included in the multi-marker model, syndecan-1 levels influenced mortality more significantly than NT-proBNP or troponin. A multivariable regression including syndecan-1, NT-proBNP and troponin provided additional prognostic value compared to each independent biomarker. (4) Conclusions: Syndecan-1 can be considered a promising novel biomarker in acute HF, exhibiting adequate diagnostic and prognostic value. Additionally, syndecan-1 can be used as a surrogate biomarker for non-cardiac organ dysfunction, as its highs levels can accurately reflect early acute kidney and liver injury.

show abstract

Section: Discussionmentioning

confidence: 99%

Syndecan-1: From a Promising Novel Cardiac Biomarker to a Surrogate Early Predictor of Kidney and Liver Injury in Patients with Acute Heart Failure

Miftode

Costache

Constantinescu

et al. 2023

Life

View full text Add to dashboard Cite

show abstract

“…More important, in a recent study, Vo revealed that syndecan-1 is markedly expressed even in early atheromatous lesions of aorta, such as fatty streaks and fibrolipidic lesions [25]. Syndecan-1 is found particularly on intimal smooth muscle cells, favouring the accumulation of foam cells.…”

Section: Syndecan-1 In Ischemic Heart Failure: Its Importance In Tmentioning

confidence: 99%

Syndecan-1: A Review on Its Role in Heart Failure and Chronic Liver Disease Patients’ Assessment

Miftode

Șerban

Timpau

et al. 2019

Cardiology Research and Practice

View full text Add to dashboard Cite

The close connection and interaction between the cardiac and the liver functions are well-known, as cirrhotic cardiomyopathy is an important clinical entity which best describes the mutual pathogenical influence between these two organs. Due to the fact that cardiac dysfunction in patients with chronic hepatic disorders is oligosymptomatic or even asymptomatic, an early diagnosis represents a challenge for every physician. Syndecan-1—a transmembrane proteoglycan that exerts its functions mainly via its heparane sulfate chains—is a very promising biomarker, correlated not only with the degree of cardiac fibrosis but also with the severity of liver fibrosis. Many studies highlighted its role in the development of cardiac fibrosis or atherogenesis, being significantly correlated with the activity of angiotensin II. Multiple evidence revealed that syndecan-1 is also associated with tissue injury and may regulate inflammatory and regenerative responses, being considered a protective molecule that limits the inflammation and reduces cardiac remodelling and dysfunction after a myocardial infarction. Syndecan-1 may also be used as a reliable biomarker for the noninvasive assessment of liver fibrosis. Under various fibrogenetic conditions, shedding of syndecan's extracellular domain took place, becoming a soluble form that binds different growth factors and inhibits further fibrosis. This complex molecule is also involved in the lipid metabolism, by altering the clearance of cholesterol particles, and in chronic hepatitis, by enhancing the viral invasion of hepatocytes. Due to the growing interest in this biomarker, multiple studies aimed at revealing syndecan-1's potential benefits in the diagnosis and prognosis assessment in patients with heart failure or chronic liver disorders. In this review, we review the mechanisms by which syndecan-1 exerts its effects and the possible perspectives opened by its use as a dual cardio-hepatic biomarker.

show abstract

Syndecan-1 is overexpressed during atherogenesis

Cited by 2 publications

References 0 publications

Syndecan-1: From a Promising Novel Cardiac Biomarker to a Surrogate Early Predictor of Kidney and Liver Injury in Patients with Acute Heart Failure

Syndecan-1: From a Promising Novel Cardiac Biomarker to a Surrogate Early Predictor of Kidney and Liver Injury in Patients with Acute Heart Failure

Syndecan-1: A Review on Its Role in Heart Failure and Chronic Liver Disease Patients’ Assessment

Contact Info

Product

Resources

About